"The U.S. Food and Drug Administration today approved Vimizim (elosulfase alfa), the first FDA-approved treatment for Mucopolysaccharidosis Type IVA (Morquio A syndrome). Morquio A syndrome is a rare, autosomal recessive lysosomal storage disease "...
(Generic versions may still be available.)
At present there are no known contraindications to the use of PROVISC (sodium hyaluronate) Viscoelastic Preparation when used as recommended; care should be used in patients with hypersensitivity to any components in this material (see Precautions).
Last reviewed on RxList: 2/15/2005
This monograph has been modified to include the generic and brand name in many instances.
Additional Provisc Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.